ASCLETIS-B(01672) will showcase data from multiple projects at the 33rd European Obesity Congress (ECO 2026).

ASCLETIS-B (01672) announcement, will showcase multiple projects in the form of posters at the 33rd European Obesity Conference (ECO 2026) in Istanbul, Turkey from May 12-15, 2026. The display will include a poster on the Phase I data of ASC47 (a fat-targeting thyroid hormone receptor beta (THR) agonist for weight loss without muscle loss), showing a relative increase of up to 111.8% when combined with simegluride compared to simegluride alone in obese subjects; as well as a poster on preclinical data of ASC36 (a once-monthly novel glucagon receptor agonist peptide), with an average apparent half-life of 32 days in non-human primate models, six times longer than petrelintide, and a relative increase of 91% in weight loss compared to petrelintide in diet-induced obese (DIO) rat models.